UNLABELLED: Continence problems during treatment with orlistat (a lipase inhibitor) are caused when susceptible patients are exposed to increased volumes of loose, fatty stool. AIM: To investigate the dose-response effects of loperamide on continence and anorectal function in subjects susceptible to continence problems on orlistat. METHOD:Ten obese subjects enterred a randomized controlled, double-blind study of loperamide at placebo, 2, 4, and 6 mg/day in a factorial design. Continence problems during orlistat treatment were self-assessed by patient diary. Anorectal function and continence were assessed by barostat, manometry, and retention testing. RESULTS:Loperamide increased stool consistency with dose (p = 0.07) and this effect reduced continence problems during orlistat treatment (p < 0.05). A bell-shaped dose-response relationship was present with anal sphincter function (p < 0.01) and anorectal sensitivity (p < 0.01). CONCLUSION:Loperamide has beneficial effects on stool consistency and continence in obese subjects taking orlistat. The effect on stool consistency appeared more important than effects on anorectal function.
RCT Entities:
UNLABELLED: Continence problems during treatment with orlistat (a lipase inhibitor) are caused when susceptible patients are exposed to increased volumes of loose, fatty stool. AIM: To investigate the dose-response effects of loperamide on continence and anorectal function in subjects susceptible to continence problems on orlistat. METHOD: Ten obese subjects enterred a randomized controlled, double-blind study of loperamide at placebo, 2, 4, and 6 mg/day in a factorial design. Continence problems during orlistat treatment were self-assessed by patient diary. Anorectal function and continence were assessed by barostat, manometry, and retention testing. RESULTS:Loperamide increased stool consistency with dose (p = 0.07) and this effect reduced continence problems during orlistat treatment (p < 0.05). A bell-shaped dose-response relationship was present with anal sphincter function (p < 0.01) and anorectal sensitivity (p < 0.01). CONCLUSION:Loperamide has beneficial effects on stool consistency and continence in obese subjects taking orlistat. The effect on stool consistency appeared more important than effects on anorectal function.
Authors: J Eric Jelovsek; Alayne D Markland; William E Whitehead; Matthew D Barber; Diane K Newman; Rebecca G Rogers; Keisha Dyer; Anthony Visco; Vivian W Sung; Gary Sutkin; Susan F Meikle; Marie G Gantz Journal: Contemp Clin Trials Date: 2015-08-18 Impact factor: 2.226
Authors: Theodosios D Filippatos; Christos S Derdemezis; Irene F Gazi; Eleni S Nakou; Dimitri P Mikhailidis; Moses S Elisaf Journal: Drug Saf Date: 2008 Impact factor: 5.606
Authors: J Eric Jelovsek; Alayne D Markland; William E Whitehead; Matthew D Barber; Diane K Newman; Rebecca G Rogers; Keisha Dyer; Anthony G Visco; Gary Sutkin; Halina M Zyczynski; Benjamin Carper; Susan F Meikle; Vivian W Sung; Marie G Gantz Journal: Lancet Gastroenterol Hepatol Date: 2019-07-15
Authors: Isaac José Felippe Corrêa Neto; Rodrigo Ambar Pinto; José Marcio Neves Jorge; Marco Aurélio Santo; Leonardo Alfonso Bustamante-Lopez; Ivan Cecconello; Sérgio Carlos Nahas Journal: Obes Surg Date: 2017-07 Impact factor: 4.129